Mechanisms of antibiotics influence on intestine, role of Enterol in the prophylaxis and treatment of antibiotic-associated diarrhea in children
- Autores: Kornienko EA1, Kornienko E1
-
Afiliações:
- Edição: Nº 2 (2010)
- Páginas: 33-37
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278203
- ID: 278203
Citar
Texto integral
Resumo
Mechanisms of antibiotics influence on intestine, role of Enterol in the prophylaxis and treatment of antibiotic-associated diarrhea in children
Bibliografia
- Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992;15:573-81.
- Beaugerie L, Flahault A, Barbut F, et al. Antibiotic-associated diarrhea and Clostridium difficile in the community. Aliment Pharmacol Ther 2003;17:905-12.
- Bouhnik Y, Rambaut JC, Buts JP, ets. Microflora and diarrhoea: antibiotic-associated diarrhoea. Gut Microflora. 2006;181-197.
- Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2,462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001;47:43-50.
- McFarland LV, Brandmarker SA, Guandalini S. Pediatric Clostridium difficile: a phantom menace or clinical reality? J Pediatr Gasroenterol Nutr 2000;31:220-31.
- Delmee M, Verellen G, Avesani V, et al. Clostridium difficile in neonates: serogrouping and epidemiology. Eur J Pediatr 1988;147:36-40.
- Larson HE, Barclay FE, Honour P, et al. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982;146:727-33.
- Ferroni A, Merckx J, Ancelle T, et al. Nosocomial outbreak of Clostridium difficile diarrhea in a pediatric service. Eur J Clin Microbiol nfect Dis 1997;16:928-33.
- Rambaud JC, LaMont JT, Buts JP. The clinical significance of Clostridium difficile infections in infants and children. 1996;29-36.
- Benoit R, Danquechin DE, Loulergue J, et al. Diarroea post-antibiotique : role de Klebsiella oxytoca. Gasroenterol Clin Biol 1992;16:860-64.
- Rambaud JC, LaMont JT, Lamont JT. Recent advances in the structures and function of Clostridium difficile toxins. 1996;72-86.
- Price AB. Pseudomembranous colitis. 2005;15-172.
- Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associatied diarrhea: a review. Arch Intern Med 2000;161(525):5-33.
- Rambaud JC, Ducluzeau R, Cooperstock M. Clostridium difficile in infants and children. 1990;81-94.
- Harris PR, Figueroa-Colon R. Rectal prolapse in children associated with Clostridium difficile infection. Pediatr Infect Dis J 1995;14:78-80.
- Garlani MJ, Murray JC, Morad AB, et al. Chronic osteomyelitis caused by Clostridium difficile in an adolescent with sickle cell disease. Pediatr Infect Dis J 1996;15:1054-56.
- Thomas DFM, Fernie DS, Bayston R, et al. Clostridial toxins in neonatal necrotising enterocolitis. Arch Dis Child 1984;59:270-83.
- Cetina-Sauri G, Sierra Basto G. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Annales de Pediatrie 1994;41(6):397-400.
- Castaneda C, Garcia E, Santa Cruz M, et al. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Revista Mexicana de Puericultura y Pediatria 1995;2:12.
- Castagliuolo I, LaMont JT, Nikulasson ST, et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infection and Immunity 1996;12:5225-32.
- Gedek BR. Adherence of E.coli serogroup O-157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 1999;42(4):261-64.
- Cherucka D, Dahan S, Mograbi B, et al. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infection and Immunity 2000;68:5998-6004.
- Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infection and Immunity 2003;72(2):766-73.
- Buts JP, Bernasconi P, Van Craymest MP, et al. Response of human and rat small intestinal mucosa to oraladministration of Saccharomyces boulardii. Pediatric Research 1986;20:192-96.
- Sougiolzis S. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006;2:23.
- Girard-Pipau F, Pompei A, Schneider S, et al. Intestinal microflora, short chain and cellular fatty acids, influence of a probiotic Saccharomyces boulardii. Microb Ecolog in Health Dis 2002;14:220-27.
- Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile- associated entheropathies in infants. J Pediatr Gastroenterol Nutr 1993;16:419-25.
- Costalos C, Skouteri V, Gounaris A, et al. Enteral feeding of premature infants with Saccharomyces boulardii. Early Hum Dev 2003;11:89-96.
Arquivos suplementares
![](/img/style/loading.gif)